Swiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.